Medistem Being Acquired for $26 Million

Medistem shareholders will receive 27 cents in exchange for each share of common stock in cash, as well as $1.07 of Intrexon common stock, based on the 20-day average price of Intrexon’s common stock prior to closing, it said in a statement.

Intrexon — a “synthetic biology” company that dabbles in the health, food, energy and environmental sectors — held one of the more high-profile biotech initial public offerings in 2013, raising $160 million. Forbes reported that Kirk — one of the wealthiest biotech executives in the U.S. — netted nearly $1.5 billion as he owns some 60 percent of Intrexon’s shares.